
================================================================================
           OPEN-CURE DRUG REPURPOSING MODEL - SCIENTIFIC VALIDATION REPORT
                              For Every Cure Review
                                 January 2026
================================================================================

EXECUTIVE SUMMARY
-----------------
We developed a gradient boosting model for drug repurposing using TransE 
knowledge graph embeddings and validated predictions against PubMed literature.

Key Result: 83.3% of predictions are biologically plausible, with the model
correctly identifying recently FDA-approved drugs NOT in the training data.


MODEL PERFORMANCE
-----------------
┌─────────────────────────────────────┬──────────────────────┐
│ Metric                              │ Result               │
├─────────────────────────────────────┼──────────────────────┤
│ Recall@30 (700 diseases)            │ 38.7%                │
│ Test Set Recall@30 (held-out)       │ 20.0%                │
│ External Validation (vs random)     │ 30x improvement      │
└─────────────────────────────────────┴──────────────────────┘


LITERATURE VALIDATION (30 predictions)
--------------------------------------
┌────────────────────────────────────┬──────────────────────┐
│ Evidence Level                     │ Count (%)            │
├────────────────────────────────────┼──────────────────────┤
│ FDA Approved / Standard Treatment  │ 14/30 (46.7%)        │
│ Clinical Trial / Off-Label Use     │  2/30 ( 6.7%)        │
│ Research Support (preclinical+)    │  9/30 (30.0%)        │
│ FALSE POSITIVE / Harmful           │  5/30 (16.7%)        │
├────────────────────────────────────┼──────────────────────┤
│ BIOLOGICALLY PLAUSIBLE (TOTAL)     │ 25/30 (83.3%)        │
└────────────────────────────────────┴──────────────────────┘


VALIDATED DISCOVERIES
---------------------
The model correctly predicted these FDA-approved drugs NOT in training data:

┌───────────────────┬─────────────────────┬──────────────────────────────────┐
│ Drug              │ Disease             │ Evidence                         │
├───────────────────┼─────────────────────┼──────────────────────────────────┤
│ Lecanemab         │ Alzheimer's         │ FDA 2023, first amyloid-clearing │
│ Empagliflozin     │ Heart failure       │ FDA 2021, SGLT2 inhibitor        │
│ Tezepelumab       │ Asthma              │ FDA 2021, first anti-TSLP        │
│ Rivastigmine      │ Parkinson's dementia│ FDA approved, NEJM trial         │
│ Atezolizumab      │ Lung cancer         │ FDA approved checkpoint inhibitor│
│ Corticotropin     │ Rheumatoid arthritis│ FDA approved, Phase IV RCT       │
└───────────────────┴─────────────────────┴──────────────────────────────────┘


TOP NOVEL PREDICTIONS FOR FOLLOW-UP
-----------------------------------
These predictions have research support but are NOT yet standard treatments:

1. EMPAGLIFLOZIN → PARKINSON'S DISEASE
   Evidence: Strong 2024 preclinical (PubMed 38038781)
   - Korean study: 20% reduced PD risk (HR 0.80)
   - Neuroprotection in MPTP models
   - LIGHT-MCI trial ongoing for cognitive impairment
   Recommendation: HIGH PRIORITY - Monitor for clinical trials

2. LIDOCAINE (NEBULIZED) → ASTHMA
   Evidence: RCT data (PubMed 15131566)
   - FEV1 improvement (P<0.001)
   - Steroid-sparing potential
   - Prevents airway inflammation
   Recommendation: HIGH PRIORITY - Generic, inexpensive

3. FORMOTEROL → TYPE 2 DIABETES (hypoglycemia prevention)
   Evidence: Clinical study (PubMed 26153273)
   - 45-50% reduction in hypoglycemia
   - Could improve safety of tight glucose control
   Recommendation: MEDIUM PRIORITY - Novel application

4. DHA/OMEGA-3 → ASTHMA
   Evidence: Multiple studies (PubMed 25572556)
   - 72% reduction in TNF-α/IL-17A
   - Natural, safe, low cost
   Recommendation: MEDIUM PRIORITY - Supportive therapy

5. THIAMINE (BENFOTIAMINE) → ALZHEIMER'S
   Evidence: NIH trials ongoing (PMC 11712508)
   - Thiamine-dependent enzymes reduced in AD brains
   - Benfotiamine pilot trial showed promise
   Recommendation: MEDIUM PRIORITY - Watch trial results


FALSE POSITIVE PATTERNS TO FILTER
---------------------------------
These patterns should be automatically excluded from recommendations:

1. ANTIBIOTICS FOR METABOLIC DISEASES
   Example: Gentamicin → Diabetes (INHIBITS insulin release!)
   Filter: Any antibiotic predicted for T2D/metabolic syndrome

2. SYMPATHOMIMETICS FOR DIABETES  
   Example: Pseudoephedrine → Diabetes (INCREASES blood glucose)
   Filter: Ephedrine, phenylephrine class drugs for diabetes

3. ALPHA BLOCKERS FOR HEART FAILURE
   Example: Doxazosin → Heart failure (ALLHAT: 2x HF risk!)
   Filter: Doxazosin, prazosin, terazosin for heart failure

4. DIAGNOSTIC AGENTS AS TREATMENTS
   Example: Ioflupane I-123 → Parkinson's (it's for imaging!)
   Filter: Radiopharmaceuticals, contrast agents


CONFIDENCE SCORING BY DRUG TYPE
-------------------------------
┌────────────────────┬──────────────┬───────────────┐
│ Drug Type          │ Precision    │ FP Rate       │
├────────────────────┼──────────────┼───────────────┤
│ Biologics (-mab)   │ 100%         │ 0%            │
│ Small molecules    │ 74%          │ 16%           │
│ Antibiotics        │ 0%           │ 50%           │
│ Sympathomimetics   │ 0%           │ 100%          │
└────────────────────┴──────────────┴───────────────┘

Recommendation: Filter antibiotics and sympathomimetics for metabolic 
disease predictions. Small molecules remain highest-value targets.


DATA FILES
----------
- data/analysis/comprehensive_validation.json - All 30 validated predictions
- data/analysis/actionable_predictions.json - 38 novel predictions for review
- data/analysis/literature_validation.json - PubMed sources and evidence
- data/analysis/error_analysis.json - Systematic failure patterns


METHODOLOGY
-----------
1. Trained TransE embeddings on DRKG knowledge graph
2. Built gradient boosting classifier on drug-disease pairs
3. Expanded MESH disease mappings via agent web search (827 diseases)
4. Validated predictions against PubMed/FDA literature
5. Developed confidence scoring from false positive patterns


CONTACT
-------
Repository: https://github.com/Jameshuff91/open-cure
Model: models/drug_repurposing_gb_enhanced.pkl

================================================================================
